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Background:  VerifyNow (VN) P2Y12 assay has been increasingly used to predict thromboembolic events by measuring residual platelet reactivity 
in patients on clopidogrel therapy. The present study was conducted to investigate whether high post-clopidogrel platelet reactivity (HPPR) assessed 
by VN P2Y12 assay after percutaneous coronary intervention (PCI) is related to stent thromobosis (ST) in acute coronary syndromes (ACS).
Methods:  The study cohort was comprised of 703 ACS patients undergoing PCI from July, 2006 to March, 2007 at Wonju Christian Hospital and 
Seoul National University Hospital. P2Y12 reaction unit (PRU) and % inhibition of platelet aggregation (IPA) were measured using VN P2Y12 assay 
within 7 days following PCI. HPPR was defined as ≥ 285 IU of PRU, the higher inter-quartile value. Kaplan-Meier estimation and the Log-rank test 
were performed to compare the occurrence of ST between low (n=178) and normal responders (n=525).
Results:  ST was occurred in 21 (2.9%) of the patients. There was no difference of mean PRU and % IPA between in patients with ST and in those 
without ST. HPPR was not a predictor of ST on the multiple logistic analysis (HR 0.972, CI 0.260-3.639, p=967). Kaplan-Meier curves and the Log-
rank test showed no differences of the occurrence of ST between low and normal responders (p=0.286)
Conclusion: In ACS setting, post-PCI measurement of residual platelet reactivity assessed by VN P2y12 assay does not seem to predict the 
occurrence of stent thrombosis.
No ST (n=682) ST (n=21) P value
ARU (IU), mean (SD) 445.6 (71.5) 483.7 (92.4) 0.083
PRU (IU), mean (SD) 221.2 (84.9) 228.1 (96.8) 0.716
% IPA, mean (SD) 28.3 (23.4) 22.7 (26.9) 0.335
≥285 IU of PRU, n (%) 170 (24.9) 7 (33.3) 0.408
≤ 10 % IPA, n (%) 166 (24.3) 9 (42.8) 0.059
≥235 IU of PRU, n (%) 311 (46.6) 11 (52.3) 0.594
≤ 20 % IPA, n (%) 288 (42.2) 13 (61.9) 0.083
